December 2005 Newsletter
A frequent question in regard to the institute’s planned sponsorship of clinical studies of hydrazine sulfate is why these studies have taken so long being implemented. One of the principal reasons for this is the National Cancer Institute. As readers of the institute’s Newsletters well know, the NCI is not well oriented toward hydrazine sulfate and to this day continues to post misinformation on this drug on the Internet. The NCI has enormous influence wherever cancer research is done. And for this reason cancer centers—where cancer drugs are tested—are extremely reluctant to initiate clinical studies on hydrazine sulfate, lest their large, annual institutional and other NCI bloc and project grants dry up.
Every controlled clinical trial of hydrazine sulfate, performed in accordance with generally accepted scientific principles—without exception—has shown efficacy and safety of the drug. The only contrary studies have been those sponsored by the National Cancer Institute. But the NCI-sponsored studies violate all accepted standards of scientific conduct, in that incompatible agents (medications) were used with the test drug. Use of incompatible agents in a drug trial—or those even suspected of incompatibility—is essentially unknown.
The NCI-sponsored studies of hydrazine sulfate in effect are in violation of the Helsinki Declaration, a multinational ratification of principles governing human experimental biomedical research, to which the United States is a signatory. Basic principles 1 and 8 of this Declaration state: “Biomedical research involving human subjects must conform to generally accepted scientific principles….” and “Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.”
Nevertheless the institute’s planned sponsorship of clinical studies of hydrazine sulfate remains on course. The proposed clinical trial at St. George’s Medical University in Lucknow, India, still has further administrative hurdles to get over before being implemented. And negotiations for the proposed joint clinical trial at North Shore University Hospital in Manhasset, Long Island, are still continuing. We will keep you informed of progress on these two fronts in succeeding Newletters.
Meanwhile our Global Outreach program is in high gear, and we are providing treatment information on hydrazine sulfate to hundreds of patients and doctors alike each month, who are calling from all parts of the world. Illustrative of this is a 49-year old physician from Bombay, India, who called in regard to her 75-year old father suffering from the brain cancer, glioblastoma multiforme. He was diagnosed two and a half years ago and has been on hydrazine sulfate ever since. His life expectancy at the time was only 6 months. The doctor, his daughter, called to say that he remains symptom free and to ascertain the year old female cat, who was treated at a large university veterinary center for terminal stomach cancer with hydrazine sulfate and was responsible for the betterment of thousands of cats and dogs around the world. Elwood’s full story appears in the attached notice of the Elwood Fund. This fund will be devoted principally to treatment of pets with cancer and other diseases, dissemination of information to veterinary health care professionals and pet owners and sponsorship of new veterinary studies at veterinary centers. There are very few voices that act as advocates for these animals, and we feel it important that these beloved animals be given the best chance at life as possible.
As the Holiday Season approaches, we again ask your sponsorship of our programs. We have tried to keep you apprised of our programs. These are real programs, ongoing programs—not those of “if,” “maybe,” “we hope to”—which are saving the lives of people you will never know, or maybe those right next door to you. We ask your help. Your continuing generosity. Your participation in our vital programs holds the power of aiding many cancer patients who will otherwise have no help or hope.
I am happy to announce that SCRI this year has received a twenty-five thousand dollar donation from the Richard C. Goodwin Philanthropic Fund. Charitable donations such as these have great impact on our work. But all funds, large and small, serve a crucial purpose in our efforts and help bring our life-saving programs to those far and near. To loved ones. To your neighbors and family around the world.
Wishing you a happy and healthy Holiday Season and bountiful New Year.
Joseph Gold, M.D.
P.S. All donations to the Elwood Fund
The Elwood Fund
Elwood was a beloved seventeen-year-old cat who passed away June 16,k 2005, of kidney failure. A sleek, short-hair female cat, Elwood made medical history and was responsible for the betterment of thousands of cats and dogs around the world. In 1997 Elwood had part of her stomach removed at Cornell University Veterinary Hospital for cancer; however, the edges sewn together were full of cancer and she was not expected to live long. She returned to the clinic six weeks later emaciated. She was placed on a course of chemotherapy to be given every three weeks and on daily hydrazine sulfate, an anticancer drug developed by the Syracuse Cancer Research Institute, and was given a prognosis of “two to five months.” The chemotherapy was discontinued after the second course because of side effects, and Elwood was maintained only on daily hydrazine sulfate. After the chemotherapy was discontinued, Elwood began to nibble, then eat vigorously. Until then, the longest-lived cat on record with her disease was one year. After one year, Elwood had regained all her lost weight, having been maintained only on daily hydrazine sulfate (and a steroid), and visited the clinic every six months for the next eight years. Word of her recovery spread throughout the nation, as a result of which thousands of cats and dogs were placed on hydrazine sulfate, many of whom were reported to have recovered completely.
The Syracuse Cancer Research Institute has established the Elwood Fund, dedicated to the beneficial treatment of small animals with terminal disease, and to the dissemination of information to veterinarians and to owners of cats and dogs in regard to the therapy of these animals. Those wishing to contribute to the Elwood Fund are asked to send tax-deductible contributions to the Syracuse Cancer Research Institute, Elwood Fund, 600 E. Genesee Street, Syracuse, NY 13202. All contributions will be acknowledged.
This page is hosted by Next Generation
Computer Systems, and is the property of the Syracuse Cancer Research Institute. ©
1996, Syracuse Cancer Research Institute. All rights reserved. Last modified on